Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
  • Sadettin Uslu
    Department of Rheumatology, Ömer Halisdemir University Bor Physical Medicine and Rehabilitation, Training and Research Hospital, Niğde, Turkey


Tocilizumab, COVID-19, cytokine release syndrome


Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis. Tocilizumab (TCZ), an interleukin?6 (IL-6) inhibitor, may ameliorate the CRS associated with severe COVID?19 and thus improve clinical outcomes. We present a case of life-threatening CRS caused by COVID-19 infection successfully treated with TCZ.



  • Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.

  • Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 2018;23(8):943–947.

  • Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al., COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–1034.

  • Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun 2020 Apr 10:102452. doi: 10.1016/j.jaut.2020.102452 [Epub ahead of print].
  • Views: 1706
    HTML downloads: 130
    PDF downloads: 832

    Published: 2020-05-22
    Issue: 2020: Vol 7 No 6 (view)

    How to cite:
    Uslu S. Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome. EJCRIM 2020;7 doi:10.12890/2020_001731.